| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC5096 | Texasin | Potent and selective human leukocyte 5-lipoxygenase (5-LOX) inhibitor |
|
| DCC5097 | Tezosentan | Novel endothelin (ET) receptor antagonist |
|
| DCC5098 | Tfah-10n | Novel multipotent anti-Alzheimer agent, selectively inhibiting human butyrylcholinesterase (BChE), having strong antioxidant activity and good β-amyloid (Aβ) anti-aggregation properties |
|
| DCC5099 | Tfgf-18 | Novel GSK-3β inhibitor, showing anti-neuroinflammatory effects in lipopolysaccharide (LPS) activation of spontaneously immortalized SIM-A9 microglial cells and of mouse cortical microglia, inhibiting LPS-induced production of nitric oxide and the proinfla |
|
| DCC5100 | Tfmo-1 | Novel cell-active, selective class IIa HDAC inhibitor |
|
| DCC5101 | Tfmo-12 | CNS-penetrant selective class IIa histone deacetylase (HDAC) inhibitor, exploiting the >100-fold selectivity over class I/IIb HDACs |
|
| DCC5102 | Tfr4oht | Cyclized tamoxifen analog, selective ER modulator (SERM) |
|
| DCC5103 | Tg-0054 | Novel and Potent Stem Cell Mobilizer; Inhibitor of SDF-1α/CXCR4 binding |
|
| DCC5104 | Tg-0205221 | Novel potent SARS coronavirus (CoV) 3CL protease inhibitor (Ki = 53 nM) |
|
| DCC5105 | Tg100948 | Novel dual VEGFR/Src kinase inhibitor |
|
| DCC5106 | Tg101114 | Novel inhibitor of T315I mutant enzyme, exhibiting reasonable in vivo efficacy in a xenograft mouse model harboring T315I |
|
| DCC5107 | Tg11-77 Hydrochloride | Novel, Potent, Selective, Water Soluble, Brain-Permeable EP2 Receptor Antagonist |
|
| DCC5108 | Tg-2112x | Novel inhibitor of mitochondrial calcium uptake (#333333; font-family: "Open Sans", HelveticaNeue, "Helvetica Neue", Helvetica, Arial, sans-serif; font-size: 15px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: |
|
| DCC5109 | Tg2-in-3h | Highly selective, potent, cell-permeable fluorescent irreversible tissue transglutaminase (TG2) inhibitor |
|
| DCC5110 | Tg3-95-1 | EP2 allosteric potentiator |
|
| DCC5111 | Tg4-166 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5112 | tg4-290-1 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5113 | tg4-292-1 | Potent and selective nociceptin opioid receptor (NOP) agonist |
|
| DCC5114 | Tg4-294-2 | Potent and Selective Antagonist for Human EP2 Receptors |
|
| DCC5115 | Tgp-200c | Novel potent and structure-specific inhibitor of pre-miR-200c, reversing a type 2 diabetes phenotype |
|
| DCC5116 | Tgr5 Agonist 11d-na | Novel potent TGR5 agonist, displayind a significant glucose-lowering effect and stimulated GLP-1 and insulin secretion in TGR5H88Y mice but not in wild-type animals |
|
| DCC5117 | Tgr5-agonist-17 | Novel Potent Agonist of TGR5 Receptor |
|
| DCC5118 | Tgx-115 | Cell-permeable, potent, and selective inhibitor of PI 3-K isoforms p110ß/p110d |
|
| DCC5119 | Tgx-155 | Potent and selective inhibitor of PI 3-K |
|
| DCC5120 | Th1027 | Novel highly potent and specific inhibitor of TLR8, targeting an unconventional pocket on the TLR8 protein-protein Interface |
|
| DCC5121 | Thaigranatin T | Natural potent human carboxylesterase 2 (hCES2) inhibitor (IC50: 5.05 μM) |
|
| DCC5122 | Thalassosamide | Natural antibiotic, being active against P. aeruginosa both in vitro and in vivo. |
|
| DCC5123 | Thdp-17 | Novel glutaminase activity inhibitor, showing a partial uncompetitive inhibition in vitro and a significant reduction of ammonia and glutamate production in vivo |
|
| DCC5124 | Thiamphenicol Palmitate | Prodrug of Thiamphenicol, inhibiting the 50S subunit of the bacterial ribosome and protein translation |
|
| DCC5125 | Thiazolidinedione-8 | Novel antibiofilm agent, disturbing symbiotic balance between C. albicans and S. mutans in dual species biofilm |
|
